Ligand Pharmaceuticals Incorporated
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Ligand Pharmaceuticals Incorporated generated cash of $49,577,000, which is less than the previous year. Cash used in financing activities reached the amount of -$59,947,000 last year. Net change in cash is therefore -$22,052,000.
Cash Flow
| 2014 | 20.56M | -2.02M | 130.02M |
|---|---|---|---|
| 2015 | 41.72M | -112.86M | 8.36M |
| 2016 | 63.00M | -143.19M | 1.51M |
| 2017 | 93.56M | -84.17M | -7.52M |
| 2018 | 194.05M | -423.26M | 328.58M |
| 2019 | -29.33M | 466.91M | -485.17M |
| 2020 | 54.58M | 231.64M | -310.54M |
| 2021 | 78.79M | 30.52M | -137.76M |
| 2022 | 137.85M | 163.62M | -275.99M |
| 2023 | 49.57M | -11.68M | -59.94M |
LGND Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 45.00M | 19.52M | 47.96M | 72.27M | 119.78M | 20.62M | 18.75M | 97.42M | 160.20M | 11.63M |
Operating activities | ||||||||||
Net income | 52.15M | -33.36M | 57.13M | -2.98M | 629.30M | 143.32M | 12.55M | -2.36M | 254.92M | 10.89M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 35.64M | 51.37M | 50.94M | 27.96M | 43.73M | 14.71M | 11.71M | 11.29M | 2.62M | 2.65M |
Stock-based compensation expense | 25.74M | 60.28M | 38.78M | 30.72M | 24.51M | 0 | 24.91M | 18.89M | 12.45M | 11.27M |
| Deferred income tax benefit | 25.74M | 60.28M | 38.78M | 30.72M | 24.51M | 0 | 24.91M | 18.89M | 12.45M | 11.27M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -2.60M | 55.31M | -28.61M | -26.06M | 25.46M | -29.54M | -8.35M | -8.52M | 6.48M | -10.41M |
Inventories | -10.87M | 12.05M | -427K | -17.79M | -2.06M | -2.55M | -843K | -244K | -401K | 4.36M |
Accounts payable | -4.70M | -3.34M | -1.16M | -1.24M | -18.04M | -4.54M | -1.71M | -2.36M | -4.02M | -3.15M |
Cash generated by operating activities | 49.57M | 137.85M | 78.79M | 54.58M | -29.33M | 194.05M | 93.56M | 63.00M | 41.72M | 20.56M |
Investing activities | ||||||||||
Purchases Of Investments | -126.76M | -51.22M | -181.32M | -422.52M | -2.35B | -1.43B | -254.25M | -164.43M | -166.02M | 0 |
Investments In Property Plant And Equipment | -3.52M | -17.92M | -8.76M | -4.45M | -2.55M | -11.88M | -7.15M | -28.32M | -10.86M | -4.49M |
Acquisitions Net | -10.40M | -750K | 494K | -383.32M | -12.84M | -5.85M | -26.65M | -94.20M | -9.24M | -3.49M |
Cash generated by investing activities | -11.68M | 163.62M | 30.52M | 231.64M | 466.91M | -423.26M | -84.17M | -143.19M | -112.86M | -2.02M |
Financing activities | ||||||||||
Common Stock Issued | 22.44M | 0 | 33.76M | 3.01M | 0 | 110.18M | 0 | 6.41M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -4.54M | -8.23M | -18.44M | -77.99M | -453.04M | -122.86M | -1.96M | -3.90M | -489K | -67.95M |
Repayments of term debt | -76.89M | -261.00M | -164.94M | -231.75M | -27.32M | -217.67M | 0 | 0 | 0 | -9.36M |
Cash used in financing activities | -59.94M | -275.99M | -137.76M | -310.54M | -485.17M | 328.58M | -7.52M | 1.51M | 8.36M | 130.02M |
Net Change In Cash | -22.05M | 25.48M | -28.44M | -24.31M | -47.50M | 99.16M | 1.86M | -78.67M | -62.77M | 148.56M |
Cash at end of period | 22.95M | 45.00M | 19.52M | 47.96M | 72.27M | 119.78M | 20.62M | 18.75M | 97.42M | 160.20M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |